echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > A commonly used OTC nationwide recalled pharmacy is suspended from sale

    A commonly used OTC nationwide recalled pharmacy is suspended from sale

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    This kind of commonly used OTC has been recalled nationwide, and pharmacies have stopped selling it.


    This kind of common OTC, national recall

    This kind of common OTC, national recall

    According to the Nanguo Morning Post, it was learned from the Drug Administration of Guangxi Zhuang Autonomous Region on March 17 that the compound honeysuckle granules produced by Guangxi Lingyun County Pharmaceutical Co.


    The Guangxi Food and Drug Administration noticed that during the supervision and inspection, the bureau found that your company's production quality management was chaotic, the records were untrue, and the production process could not be traced back.


    According to the notice, in order to control risks, in accordance with the relevant provisions of the "Drug Administration Law" and "Drug Recall Management Measures", your company is now ordered to suspend the sale and use of compound honeysuckle granules and fully recall them.


    Posting documents in many provinces, pharmacies stop selling off the shelves

    Posting documents in many provinces, pharmacies stop selling off the shelves

    It is understood that the Guangxi Food and Drug Administration has issued a cooperative recall letter to the Food and Drug Administration of many provinces.


    The "Notice on Suspension of Operation and Use of Compound Honeysuckle Granules of Guangxi Lingyun Pharmaceutical Co.


    The Sichuan Provincial Food and Drug Administration requires that all municipal (prefecture) market bureaus and inspection branches of the Provincial Food and Drug Administration immediately supervise and urge drug dealers and users within their jurisdictions to take risk control measures such as suspension of sales and use and removal of the above-mentioned products, and assist in doing a good job Relevant work on drug recalls and strengthen risk monitoring of the product.


    The "Notice on Assisting the Recall of Compound Honeysuckle Granules from Guangxi Lingyun County Pharmaceutical Co.


    The Heilongjiang Provincial Drug Administration issued a document stating that in order to control risks in a timely manner, after a research decision, the municipal (prefectural) market supervision administrations notified the drug retail enterprises in their jurisdictions, and the inspection offices of the provincial bureaus notified the drug wholesale companies in their jurisdictions to immediately remove the product and cooperate The listing holder initiates a product recall.


    The Yunnan Provincial Food and Drug Administration also talked about the decision to stop the sales, use and full recall of the compound honeysuckle granules produced by Guangxi Lingyun County Pharmaceutical Co.


    The Fujian Provincial Food and Drug Administration requires all drug inspection offices to supervise and urge drug dealers and users within their jurisdiction to immediately suspend the sales and use of compound honeysuckle granules produced by Guangxi Lingyun County Pharmaceutical Co.


    Attention pharmacies, the minimum fine for failure to cooperate with the recall is 100,000

    Attention pharmacies, the minimum fine for failure to cooperate with the recall is 100,000

    Article 135 of the new version of the "Drug Administration Law" stipulates that after the drug regulatory department of the people's government of the province, autonomous region, or municipality orders the recall of the drug, if the holder refuses the recall, the value of the drug should be recalled.


    If the circumstances are serious, the drug approval documents, drug production license, and drug business license shall be revoked, and the legal representative, the main person in charge, the directly responsible person in charge, and other responsible persons shall be punished with a penalty of not less than 20,000 yuan but not more than 200,000 yuan fine.


    If a drug manufacturer, drug distributor, or medical institution refuses to cooperate with the recall, a fine of not less than 100,000 yuan but not more than 500,000 yuan shall be imposed.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.